Wall Street Zen

Company

Last mentioned: 6d ago

Share

Across the most recent 17 stories covering Wall Street Zen — 100% neutral sentiment, averaging 5/10 impact.

This entity profile aggregates every story where the entity meets our minimum relevance threshold before it is linked here — a story naming this entity only in passing, as competitive context for an unrelated subject, does not qualify. That threshold exists because earlier testing surfaced entity pages cluttered with tangential mentions: a story about two unrelated companies merging could otherwise populate a third company's page simply because it was named once for comparison, with no real event of its own. The timeline below reflects genuine milestones and developments specific to this entity, cross-referenced against the same source-verification standard applied to every story on this site. Sentiment measures the directional read of each development for this entity specifically, not the overall tone of the reporting, and impact weights how consequential a development is rather than how widely it was syndicated across outlets.

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

Timeline

  1. Quarterly earnings released

    SMBC reports EPS of $1.83 vs. $1.52 estimate, revenue of $51.77M.

  2. Piper Sandler adjusts PT

    Piper Sandler reiterates Neutral, boosts target from $71 to $79.

  3. Three directors execute insider purchases

    Philip Fracassa buys 5,000 MBC shares, Paul Koonce buys 500 SR shares, and Frederick Disanto buys 1,000 EML shares, all in open-market transactions.

  4. Insider sale by EVP Windes

    EVP Richard Windes sells 2,000 shares at average $69.70, totaling $139,400.

  5. Weiss Ratings reiterates Buy

    Weiss Ratings issues a 'buy (b)' rating on SMBC.

  6. Eastern reports Q1 2026 earnings

    EML delivers $0.11 EPS, missing the $0.50 estimate by $0.39; revenue of $59.68M trails the $67.74M consensus.

  7. Spire reports Q2 2026 earnings

    SR earns $3.76 per share, topping analyst expectations of $3.72 by $0.04; revenue of $1.02B misses consensus by $50M.

  8. Stephens bullish call

    Stephens reiterates Overweight rating, lifts PT to $76 from $72.

  9. RBC downgrades Eastern to Hold

    Royal Bank of Canada cuts EML from Moderate Buy to Hold, likely after earnings miss.

  10. KBW target price increase

    Keefe, Bruyette & Woods raises price target from $64 to $65, maintaining Market Perform rating.

  11. Sentiment Review

    Major analysts maintain existing price targets and ratings despite the earnings beat.

  12. Wall Street Zen Downgrade

    Official rating cut to Hold for both TEAM and ON tickers.

  13. Market Warnings

    Analysts warn of a 'chaos tsunami' in the workforce due to rapid AI integration at tech firms.

  14. Analyst Upgrade

    Wall Street Zen upgrades CDXS rating following financial results.

  15. Insider Selling

    President and another insider sell a combined 33,157 shares.

  16. Atlassian AI Layoffs

    Reports emerge of Atlassian cutting staff to prioritize AI agents and automation.

  17. Q4 2025 Earnings

    Codexis reports surprise profit and revenue beat.

  18. Analyst Downgrade

    Wall Street Zen cuts ALHC rating to Hold.

  19. TD Cowen Conference

    CEO touts ECO Synthesis push and 2026 inflection targets.

  20. Secondary Offering

    Company prices 13.2M shares at $19.46 to raise capital.

Stories mentioning Wall Street Zen 17

Earnings Neutral

Codexis Holds Steady as ECO Synthesis Gains Traction Post-Q4 Earnings Beat

Codexis reported a significant Q4 2025 earnings beat, driven by its ECO Synthesis platform and expanding CDMO partnerships. Despite a raised 2026 revenue outlook and a surprise GAAP profit, analyst sentiment remains largely unchanged as the market awaits further commercial validation of its RNA manufacturing technology.

2 sources
Markets Neutral

Wall Street Zen Downgrades SAB Biotherapeutics and SURO Capital to Sell

Wall Street Zen has issued 'Sell' ratings for both SAB Biotherapeutics and SURO Capital, signaling a shift in sentiment for high-risk biotech and venture-backed assets. These downgrades reflect growing analyst caution regarding clinical-stage development timelines and private equity valuation gaps in the 2026 market environment.

2 sources
Markets Neutral

Alignment Healthcare Insider Sales Follow $257M Secondary Offering

Alignment Healthcare's President and another insider divested over 33,000 shares in mid-March, following a massive secondary offering and a rating downgrade. The sales come as the Medicare Advantage provider reports narrowing losses but faces a shift in analyst sentiment from 'Buy' to 'Hold.'

2 sources
Markets Neutral

Wall Street Zen Downgrades Alignment Healthcare and Freshworks to Hold

Wall Street Zen has lowered its investment ratings for Alignment Healthcare and Freshworks from Buy to Hold, signaling a shift to a neutral outlook. The downgrades reflect a cautious stance on the Medicare Advantage sector and the competitive SaaS landscape as both companies navigate evolving market dynamics in early 2026.

2 sources
Markets Neutral

Wall Street Zen Issues Multi-Sector Downgrades for FEED, CLBT, and MVIS

Wall Street Zen has issued a series of ratings downgrades targeting a diverse group of companies including NanoVibronix, Cellebrite, MicroVision, and The Honest Company. These moves signal a shift in sentiment toward high-growth and speculative tech sectors as analysts re-evaluate valuation and performance metrics.

4 sources
Markets Neutral

Wall Street Zen Issues Bullish Upgrades for WFRD, DCBO, and ORGO

Analyst firm Wall Street Zen has issued significant rating upgrades for Weatherford International, Docebo, and Organogenesis. These shifts to 'Buy' and 'Strong-Buy' status signal a positive fundamental outlook across the energy, enterprise software, and healthcare sectors.

3 sources
Markets Neutral

Momentum Plays: Edgewise and Ericsson Hit 52-Week Highs Amid Sector Shifts

Edgewise Therapeutics and Ericsson have both breached 52-week price peaks, signaling robust investor confidence in biotech innovation and telecom infrastructure recovery. While Edgewise benefits from clinical momentum in muscle disease treatments, Ericsson's ascent reflects a stabilized global 5G landscape and a strategic pivot toward AI-native networking.

2 sources

About Wall Street Zen coverage

This page surfaces every story mentioning Wall Street Zen across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.

Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.

Entities only appear on this page once the classifier scores them at a minimum 35 percent relevance to the story, filtering out passing mentions. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.

What you seeWhat it tells you
Story countNumber of distinct stories where Wall Street Zen was a primary or referenced actor.
Recency clusteringWhether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc).
Sentiment distributionAggregate sentiment of the stories mentioning this entity, weighted by impact score.
Cross-niche linksWhen the same entity surfaces in our sibling networks, we link to those views to enrich context.